Otsuka gobbles up more global rights for Akebia’s vadadustat, chipping in to a pot now worth $2B-plus
Late last year Otsuka stepped in with a deal worth more than a billion dollars to partner with Akebia on its experimental anemia drug vadadustat in the US market. But the pact evidently only whetted its appetite for more.
In a deal extension announced after the market closed on Tuesday, Otsuka came back to grab Europe, China, Russia and much of the rest of the world, paying another $208 million in committed capital covering $73 million upfront and $135 million to cover development costs. There’s also $657 million in potential milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.